Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma)

SIMPLE SUMMARY: Over the past decades, the multi-drug approach for treating various types of cancers was highly recommended. The aim of this study was to demonstrate the advantage of treating different carcinoma types with several combinations of immune checkpoint inhibitors (ICIs) and tyrosine kina...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Cancers (Basel)
Main Authors: Shalata, Walid, Iraqi, Muhammed, Bhattacharya, Baisali, Fuchs, Vered, Roisman, Laila C., Cohen, Ahron Yehonatan, Massalha, Ismaell, Yakobson, Alexander, Prasad, Manu, Elkabets, Moshe, Porgador, Angel, Peled, Nir
פורמט: Artigo
שפה:Inglês
יצא לאור: MDPI 2021
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC8307809/
https://ncbi.nlm.nih.gov/pubmed/34298855
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13143630
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים